Shareholders approve record-breaking compensation plan tied to ambitious goals in vehicles, robotics, and AI.
Tesla (TSLA) CEO Elon Musk has secured shareholder approval for a pay package that could ultimately reach nearly $1 trillion, setting in motion one of the most ambitious executive incentive plans in corporate history. The plan, revealed in September, ties Musk’s potential windfall to a series of aggressive operational and market capitalization milestones that could reshape Tesla’s long-term future.
Under the approved structure, Musk will receive 12 tranches of stock options totaling roughly 424 million shares, which could raise his control of Tesla from 13% to about 25%. Each tranche requires the company to meet both operational milestones—such as delivering its 20 millionth vehicle, deploying 1 million robotaxis, or selling 1 million Optimus humanoid robots—and market cap thresholds starting at $2 trillion and culminating at an extraordinary $8.5 trillion.
For context, Tesla’s EBITDA last year was $16.6 billion, far below the $400 billion operational target required to unlock full compensation. Musk’s shares will also be locked in for at least 7.5 years, preventing immediate liquidation and ensuring long-term commitment.
While critics—including proxy adviser Glass Lewis—called the payout excessive, supporters argue it aligns Musk’s incentives with shareholder value creation. Tesla’s board contends the package ensures Musk remains focused on Tesla’s next growth phase across autonomous driving, robotics, and AI.
Analysts like Wedbush’s Dan Ives believe these milestones are not entirely out of reach. “We continue to believe Tesla could reach a $2 trillion market cap early in 2026 and $3 trillion by the end of 2026,” Ives wrote, citing Tesla’s accelerating production and AI-driven roadmap.
Whether Tesla achieves Musk’s $8.5 trillion dream remains uncertain, but the approved plan cements his stake in leading one of the boldest growth experiments in modern capitalism.
You might like this article:Eli Lilly and Novo Nordisk Strike Weight-Loss Drug Deal with Trump Administration
